Evidence map›Paper›PMID 35313961›Full record

ArticleStem cell research & therapy2022

Prkg2 regulates alveolar type 2-mediated re-alveolarization.

Mo Zhang, Gibran Ali, Satoshi Komatsu, Runzhen Zhao, Hong-Long Ji

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Loss ofAmerican journal of respiratory cell and molecular biology · 2025
    Article
  3. TBX4 in Pulmonary Hypertension: Linking Lung Development to Precision Therapy.American journal of respiratory cell and molecular biology · 2025
    Article
  4. Diagnostics (Basel, Switzerland) · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Mo Zhang *Department of Cellular and Molecular Biology, University of Texas at Tyler, 11937 US Highway 271, Tyler, TX, 75708-3154, USA.
Gibran Ali *Department of Cellular and Molecular Biology, University of Texas at Tyler, 11937 US Highway 271, Tyler, TX, 75708-3154, USA.
Satoshi KomatsuDepartment of Cellular and Molecular Biology, University of Texas at Tyler, 11937 US Highway 271, Tyler, TX, 75708-3154, USA.
Runzhen ZhaoDepartment of Cellular and Molecular Biology, University of Texas at Tyler, 11937 US Highway 271, Tyler, TX, 75708-3154, USA.
Hong-Long JiDepartment of Cellular and Molecular Biology, University of Texas at Tyler, 11937 US Highway 271, Tyler, TX, 75708-3154, USA. james.ji@uthct.edu.ORCID 0000-0002-3228-7144
The University of Texas at Tyler · US

Funding

NOVEL PARACRINE MECHANISMS FOR CELL-BASED THERAPY OF INJURED LUNGSR01HL134828 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI JI, HONG-LONG · 2017 to 2025
$3.4M
NHLBI NIH HHS R01 HL134828NIH HHS HL134828
6 · The paper itself

Abstract

backgroundThe cGMP-dependent type 2 protein kinase, encoded by the prkg2 gene, is highly expressed in alveolar type 2 epithelial (AT2) cells. It is unclear whether prkg2 regulates AT2 cell homeostasis and re-alveolarization of injured lungs. This study aimed to investigate the role of prkg2 in the regulation of the fate of AT2 in vitro.

methodsPrimary AT2 cells of wild-type (wt) and prkg2

resultsPrkg2

conclusionsPrkg2 may regulate the lineage of AT2 cells, which is affected by endotoxins and the interactive PKA signaling pathway.

Indexed as

LungOrganogenesisAnimalsCells, CulturedCoculture TechniquesMiceSignal TransductionDifferentiationLung injuryOrganoidsPrkg2Proliferation

Identifiers

PMID35313961
PMCPMC8935727
OpenAlexW4221094516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.